MIME-Version: 1.0 X-Document-Type: Workbook Content-Type: multipart/related; boundary="----=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Workbook.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

This page should be opened with Microsoft Excel XP or newer.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet01.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Document And Entity Information	3 Months Ended
Mar. 31, 2012	Apr. 27, 2012
Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1
Entity Registrant Name	GILEAD SCIENCES INC
Entity Central Index Key	0000882095
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		757,321,824

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet02.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Assets [Abstract]
Cash and cash equivalents	$ 1,451,942	$ 9,883,777
Short-term marketable securities	0	16,491
Accounts receivable, net	2,163,659	1,951,167
Inventories	1,418,033	1,389,983
Deferred tax assets	193,938	208,155
Prepaid taxes	333,739	246,444
Prepaid expenses	89,592	95,922
Other current assets	175,629	126,846
Total current assets	5,826,532	13,918,785
Property, plant and equipment, net	782,867	774,406
Noncurrent portion of prepaid royalties	169,836	174,584
Noncurrent deferred tax assets	107,729	144,015
Long-term marketable securities	48,168	63,704
Intangible Assets, Net (Excluding Goodwill)	11,767,027	1,062,864
Goodwill	1,078,919	1,004,102
Other noncurrent assets	169,308	160,674
Total assets	19,950,386	17,303,134
Liabilities and Stockholders' Equity
Accounts payable	1,339,257	1,206,052
Accrued government rebates	652,703	547,473
Accrued compensation and employee benefits	136,626	173,316
Income taxes payable	14,491	40,583
Other accrued liabilities	593,063	471,129
Deferred revenues	100,191	74,665
Current portion of long-term debt and other obligations, net	1,351,573	1,572
Total current liabilities	4,187,904	2,514,790
Long-term deferred revenues	26,506	31,870
Long-term Debt, net	8,077,246	7,605,734
Long-term income taxes payable	140,655	135,655
Other long-term obligations	153,991	147,736
Stockholders' equity:
Preferred stock, par value $0.001 per share; 5,000 shares authorized; none outstanding	0	0
Common stock, par value $0.001 per share; 2,800,000 shares authorized; 758,190 and 753,106 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively	758	753
Additional paid-in capital	5,100,624	4,903,143
Accumulated other comprehensive income	33,591	58,200
Retained earnings	2,178,639	1,776,760
Total Gilead stockholders' equity	7,313,612	6,738,856
Noncontrolling interest	50,472	128,493
Total stockholders' equity	7,364,084	6,867,349
Total liabilities and stockholders' equity	$ 19,950,386	$ 17,303,134

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet03.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,800,000	2,800,000
Common stock, shares issued	758,190	753,106
Common stock, shares outstanding	758,190	753,106

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet04.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Statements Of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Revenues:
Product Sales	$ 2,208,342	$ 1,863,578
Royalty revenues	71,105	58,665
Contract and other revenues	3,002	3,851
Total revenues	2,282,449	1,926,094
Costs and expenses:
Cost of goods sold	580,931	474,111
Research and development	458,211	254,446
Selling, general and administrative	443,121	295,568
Total costs and expenses	1,482,263	1,024,125
Income from operations	800,186	901,969
Interest expense	(97,270)	(41,216)
Interest and other income, net	(34,085)	13,832
Income before provision for income taxes	668,831	874,585
Provision for income taxes	231,300	227,282
Net Income	437,531	647,303
Net Income (Loss) Attributable to Noncontrolling Interest	4,425	3,838
Net income Attributable to Gilead	$ 441,956	$ 651,141
Net income per share attributable to Gilead common stockholders - basic	$ 0.58	$ 0.82
Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders	756,286	796,115
Net income per share attributable to Gilead common stockholders - diluted	$ 0.57	$ 0.8
Shares used in per share calculation - diluted	777,388	811,857

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet05.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Operating Activities:
Net Income	$ 437,531	$ 647,303
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense	19,710	18,285
Amortization expense	46,457	62,629
Stock-based compensation expenses	48,731	49,470
Excess tax benefits from stock-based compensation	(23,304)	(14,255)
Tax benefits from employee stock plans	18,153	12,136
Deferred income taxes	51,385	20,546
Other non-cash transactions	13,767	(7,249)
Changes in operating assets and liabilities:
Accounts receivable, net	(196,531)	(107,876)
Inventories	(26,833)	(97,174)
Prepaid expenses and other assets	(75,176)	(23,903)
Accounts payable	(107,652)	(176,114)
Income taxes payable	99,151	(31,473)
Accrued liabilities	110,402	61,414
Deferred revenues	(20,176)	8,371
Net cash provided by operating activities	452,969	820,542
Investing Activities:
Purchases of marketable securities	0	(1,519,142)
Proceeds from sales of marketable securities	56,719	1,285,547
Proceeds from maturities of marketable securities	0	169,189
Acquisitions, net of cash acquired	(10,751,636)	(221,105)
Payments to Acquire Investments	(25,000)	0
Capital expenditures and other	(23,199)	(14,870)
Net cash used in investing activities	(10,743,116)	(300,381)
Financing Activities:
Proceeds from issuances of senior notes, net of issuance costs	0	987,370
Proceeds from issuances of common stock	132,530	58,879
Proceeds from (Payments for) Other Financing Activities	1,146,844	0
Proceeds from credit facility	997,889	0
Repayments of credit facility	(350,000)	0
Repurchases of common stock	(20,770)	(548,699)
Repayments of other long-term obligations	(612)	(1,533)
Excess tax benefits from stock-based compensation	23,304	14,255
Distributions (to) from noncontrolling interest	(73,595)	(25,162)
Net cash used in financing activities	1,855,590	485,110
Effect of exchange rate changes on cash	2,722	(77,172)
Net change in cash and cash equivalents	(8,431,835)	928,099
Cash and cash equivalents at beginning of period	9,883,777	907,879
Cash and cash equivalents at end of period	$ 1,451,942	$ 1,835,978

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet06.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Statements of Comprehensive Income (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Statement of Income and Comprehensive Income [Abstract]
Net Income	$ 437,531	$ 647,303
Foreign Currency Translation Gain	4,897	7,194
Net Unrealized Loss, Net of Tax	(463)	(1,684)
Reclassifications to Net Income, Net of Tax	30,600	(1,435)
Net Change	30,137	(3,119)
Net Unrealized Loss, Net of Tax	(48,816)	(126,331)
Reclassifications to Net Income, Net of Tax	(10,827)	(9,838)
Net Change	(59,643)	(136,169)
Other Comprehensive Loss	(24,609)	(132,094)
Comprehensive Income	412,922	515,209
Comprehensive Loss Attributable to Noncontrolling Interest	4,425	3,838
Comprehensive Income Attributed to Gilead	$ 417,347	$ 519,047

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet07.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Condensed Consolidated Statement of Comprehensive Income Paranthetical (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Statement of Income and Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	$ 266	$ (372)
Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax	(519)	(899)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	1,802	1,168
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax	$ (400)	$ (91)

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet08.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary Of Significant Accounting Policies	3 Months Ended
Mar. 31, 2012
Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of Gilead Sciences, Inc. (Gilead, we or us) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, intangible assets, allowance for doubtful accounts, prepaid royalties, clinical trial accruals, our tax provision and stock-based compensation. We base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and our joint ventures with Bristol-Myers Squibb Company (BMS), for which we are the primary beneficiary. We record a noncontrolling interest in our Condensed Consolidated Financial Statements to reflect BMS’s interest in the joint ventures. All intercompany transactions have been eliminated. The Condensed Consolidated Financial Statements include the results of companies acquired by us from the date of each acquisition for the applicable reporting periods. The accompanying Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2011, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC). Certain amounts within our Condensed Consolidated Balance Sheets have been reclassified to conform to the current presentation. Net Income Per Share Attributable to Gilead Common Stockholders Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options, performance shares and the assumed exercise of warrants relating to the convertible senior notes due in May 2013 (May 2013 Notes), May 2014 (May 2014 Notes) and May 2016 (May 2016 Notes) (collectively, the Convertible Notes) are determined under the treasury stock method. Because the principal amount of the Convertible Notes will be settled in cash, only the conversion spread relating to the Convertible Notes is included in our calculation of diluted net income per share attributable to Gilead common stockholders. Our common stock resulting from the assumed settlement of the conversion spread of the Convertible Notes has a dilutive effect when the average market price of our common stock during the period exceeds the conversion prices of $38.10, $45.08 and $45.41 for the May 2013 Notes, May 2014 Notes and May 2016 Notes, respectively. In 2011, our convertible senior notes due in May 2011 (May 2011 Notes) matured and the related warrants expired and as a result, we have only considered their impact for the period they were outstanding on our net income per share calculations. Our common stock resulting from the assumed settlement of the conversion spread of the May 2011 Notes had a dilutive effect when the average market price of our common stock during the period exceeded the conversion price of $38.75. During the three months ended March 31, 2011, the average market price of our common stock exceeded the conversion price of the May 2011 Notes and the dilutive effect is included in the accompanying table. Warrants related to the May 2011 Notes had a dilutive effect when the average market price of our common stock during the period exceeded the warrants’ exercise price of $50.80. The average market price of our common stock during the three months ended March 31, 2011 did not exceed the warrants’ exercise price related to the May 2011 Notes; therefore, these warrants did not have a dilutive effect on our net income per share for that period. During the three months ended March 31, 2012, the average market price of our common stock exceeded the conversion prices of the May 2013 Notes, May 2014 Notes and May 2016 Notes and the dilutive effects are included in the accompanying table. During the three months ended March 31, 2011, the average market price of our common stock exceeded the conversion price of the May 2013 Notes and the dilutive effect is included in the accompanying table. During the three months ended March 31, 2011, the average market price of our common stock did not exceed the conversion prices of the May 2014 Notes and May 2016 Notes and therefore, these notes did not have a dilutive effect on our net income per share for that period. Warrants relating to the May 2013 Notes, May 2014 Notes and May 2016 Notes have a dilutive effect when the average market price of our common stock during the period exceeds the warrants’ exercise prices of $53.90, $56.76 and $60.10, respectively. The average market prices of our common stock during each of the three months ended March 31, 2012 and 2011 did not exceed the warrants’ exercise prices relating to any of the Convertible Notes; therefore, these warrants did not have a dilutive effect on our net income per share for those periods. Stock options to purchase approximately 10.9 million and 22.1 million weighted-average shares of our common stock were outstanding during the three months ended March 31, 2012 and 2011, respectively, but were not included in the computation of diluted net income per share attributable to Gilead common stockholders because their effect was antidilutive. The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in thousands):   Three Months Ended   March 31,   2012   2011 Numerator:       Net income attributable to Gilead $ 441,956   $ 651,141 Denominator:       Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders 756,286   796,115 Effect of dilutive securities:       Stock options and equivalents 14,873   15,007 Conversion spread related to the May 2011 Notes —   224 Conversion spread related to the May 2013 Notes 3,423   511 Conversion spread related to the May 2014 Notes 1,505   — Conversion spread related to the May 2016 Notes 1,301   — Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders 777,388   811,857 Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. The majority of our trade accounts receivable arises from product sales in the United States and Europe. As of March 31, 2012, our accounts receivable in Southern Europe, specifically Greece, Italy, Portugal and Spain, totaled approximately $1.25 billion, of which $719.5 million were greater than 120 days past due and $313.3 million were greater than 365 days past due. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowance for doubtful accounts was adequate at March 31, 2012. Recent Accounting Pronouncements There have been no new accounting pronouncements during the three months ended March 31, 2012 that are of significance to us.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet09.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements	3 Months Ended
Mar. 31, 2012
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: • Level 1 inputs which include quoted prices in active markets for identical assets or liabilities; • Level 2 inputs which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and • Level 3 inputs which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable, foreign currency exchange forward and option contracts, accounts payable, and short-term and long-term debt. Cash and cash equivalents, marketable securities and foreign currency exchange contracts that hedge accounts receivable and forecasted sales are reported at their respective fair values on our Condensed Consolidated Balance Sheets. The carrying value and fair value of the Convertible Notes were $2.94 billion and $3.99 billion, respectively, as of March 31, 2012. The carrying value and fair value of the Convertible Notes were $2.92 billion and $3.53 billion, respectively, as of December 31, 2011. In March 2011, we issued senior unsecured notes due in April 2021 (April 2021 Notes) in a registered offering for an aggregate principal amount of $1.00 billion. The carrying value and fair value of the April 2021 Notes were $992.3 million and $1.06 billion, respectively, as of March 31, 2012. The carrying value and fair value of the April 2021 Notes were $992.1 million and $1.06 billion, respectively, as of December 31, 2011. In December 2011, we issued senior unsecured notes due in December 2014 (December 2014 Notes), December 2016 (December 2016 Notes), December 2021 (December 2021 Notes) and December 2041 (December 2041 Notes) in a registered offering for an aggregate principal amount of $3.70 billion. The carrying value and fair value of these notes were $3.69 billion and $3.89 billion, respectively, as of March 31, 2012. The carrying value and fair value of these notes were $3.69 billion and $3.93 billion, respectively, as of December 31, 2011. The fair values of the Convertible Notes and senior unsecured notes were determined using Level 2 inputs based on their quoted market values. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. The following table summarizes, for assets or liabilities recorded at fair value, the respective fair value and the classification by level of input within the fair value hierarchy defined above (in thousands):   March 31, 2012   December 31, 2011   Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total Assets:                               Debt securities:                               Money market funds $ 518,248   $ —   $ —   $ 518,248   $ 7,455,982   $ —   $ —   $ 7,455,982 Certificates of deposit —   —   —   —   —   1,139,982   —   1,139,982 Non-U.S. government securities —   —   —   —   —   —   24,741   24,741 Corporate debt securities —   —   —   —   —   404,989   —   404,989 Student loan-backed securities —   —   48,168   48,168   —   —   46,952   46,952 Total debt securities 518,248   —   48,168   566,416   7,455,982   1,544,971   71,693   9,072,646 Equity securities —   —   —   —   8,503   —   —   8,503 Derivatives —   51,958   —   51,958   —   100,475   —   100,475   $ 518,248   $ 51,958   $ 48,168   $ 618,374   $ 7,464,485 $ 1,645,446 $ 71,693 $ 9,181,624 Liabilities:                               Contingent consideration $ —   $ —   $ 138,328   $ 138,328   $ —   $ —   $ 135,591   $ 135,591 Derivatives —   18,404   —   18,404   —   5,710   —   5,710   $ —   $ 18,404   $ 138,328   $ 156,732   $ —   $ 5,710   $ 135,591   $ 141,301 Level 3 Inputs Assets measured at fair value using Level 3 inputs at March 31, 2012 were comprised of auction rate securities within our available-for-sale investment portfolio. The following table provides a rollforward of assets measured using Level 3 inputs (in thousands):     Three Months Ended   March 31,   2012   2011 Balance, beginning of period $ 71,693   $ 80,365 Total realized and unrealized gains (losses) included in:       Other income (expense), net (40,096 )   1,246 Other comprehensive income, net 33,094   2,160 Sales of marketable securities (16,523 )   (20,830 ) Transfers into Level 3 —   53,882 Balance, end of period $ 48,168   $ 116,823 Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. The underlying assets of our auction rate securities consist of student loans. Although auction rate securities would typically be measured using Level 2 inputs, the failure of auctions and the lack of market activity and liquidity experienced since the beginning of 2008 required that these securities be measured using Level 3 inputs. The fair value of our auction rate securities was determined using a discounted cash flow model that considered projected cash flows for the issuing trusts, underlying collateral and expected yields. Projected cash flows were estimated based on the underlying loan principal, bonds outstanding and payout formulas. The weighted-average life over which the cash flows were projected considered the collateral composition of the securities and related historical and projected prepayments. The underlying student loans have a weighted-average expected life of two to seven years. The discount rates used in our discounted cash flow model were based on market conditions for comparable or similar term asset-backed and other fixed income securities, adjusted for an illiquidity discount. This resulted in an annual discount rate of 2.18%. Our auction rate securities reset every seven to 14 days with maturity dates ranging from 2025 through 2040 and have annual interest rates ranging from 0.12% to 0.77%. As of March 31, 2012, our auction rate securities continued to earn interest. Although there continued to be failed auctions as well as lack of market activity and liquidity, we believe we had no other-than-temporary impairments on these securities as of March 31, 2012. We have the ability to hold these securities until the recovery of their amortized cost basis. In 2010, the Greek government agreed to settle the majority of its aged outstanding accounts receivable with zero-coupon bonds, which were expected to trade at a discount to face value. We estimated the fair value of the Greek zero-coupon bonds using Level 3 inputs due to the then current lack of market activity and liquidity. The discount rates used in our fair value model for these bonds were based on credit default swap rates. In March 2012, the Greek government restructured its sovereign debt which impacted all holders of Greek bonds. As a result, we recorded a $40.1 million loss related to the debt restructuring as part of other income (expense), net on our Condensed Consolidated Statement of Income and exchanged the Greek government-issued bonds for new securities, which we liquidated during the first quarter of 2012. As of March 31, 2012 and December 31, 2011, our auction rate securities were recorded in long-term marketable securities on our Condensed Consolidated Balance Sheets. As of December 31, 2011, our Greek government-issued bonds were recorded in short-term and long-term marketable securities on our Condensed Consolidated Balance Sheets. The following table provides a rollforward of our contingent consideration liabilities (in thousands):   Three Months Ended   March 31,   2012   2011 Balance, beginning of period $ 135,591   $ 11,100 Changes in valuation 2,737   — Balance, end of period $ 138,328   $ 11,100 The estimated fair value of the contingent consideration liabilities for our acquisitions was based on the present value of the total earnout amount giving consideration to significant inputs such as the probability of technical and regulatory success, the discount rate used and the timeline to achieve each of the milestone events. Significant increases in the probability of success in isolation would result in a significantly higher fair value measurement while significant decreases in the probability of success in isolation would result in a significantly lower fair value measurement. Similarly, significant increases in the discount rate or timeline in isolation would result in a significantly lower fair value measurement while significant decreases in the discount rate or timeline in isolation would result in a significantly higher fair value measurement. We evaluate changes in each of the assumptions used to calculate fair values of our contingent consideration liabilities at the end of each period.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet10.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities	3 Months Ended
Mar. 31, 2012
Investments, Debt and Equity Securities [Abstract]
Available-For-Sale Securities	AVAILABLE-FOR-SALE SECURITIES The following table is a summary of available-for-sale debt and equity securities included in cash and cash equivalents or marketable securities in our Condensed Consolidated Balance Sheets. During the quarter ended March 31, 2012, we liquidated a portion of our investment portfolio to partially fund the acquisition of Pharmasset, Inc. (Pharmasset). Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services (in thousands):   Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Estimated Fair Value March 31, 2012               Debt securities:               Money market funds $ 518,248   $ —   $ —   $ 518,248 Certificates of deposit —   —   —   — Non-U.S. government securities —   —   —   — Corporate debt securities —   —   —   — Student loan-backed securities 51,500   —   (3,332 )   48,168 Total debt securities 569,748   —   (3,332 )   566,416 Equity securities —   —   —   — Total $ 569,748   $ —   $ (3,332 )   $ 566,416 December 31, 2011               Debt securities:               Money market funds $ 7,455,982   $ —   $ —   $ 7,455,982 Certificates of deposit 1,140,000   —   (18 )   1,139,982 Non-U.S. government securities 55,246   —   (30,505 )   24,741 Corporate debt securities 404,994   —   (5 )   404,989 Student loan-backed securities 51,500   —   (4,548 )   46,952 Total debt securities 9,107,722   —   (35,076 ) 9,072,646 Equity securities 1,451   7,052   —   8,503 Total $ 9,109,173   $ 7,052   $ (35,076 )   $ 9,081,149 The following table summarizes the classification of the available-for-sale debt and equity securities on our Condensed Consolidated Balance Sheets (in thousands):   March 31, 2012   December 31, 2011 Cash and cash equivalents $ 518,248   $ 9,000,954 Short-term marketable securities —   16,491 Long-term marketable securities 48,168   63,704 Total $ 566,416   $ 9,081,149 The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):   March 31, 2012   Amortized Cost   Fair Value Less than one year $ 518,248   $ 518,248 Greater than one year but less than five years —   — Greater than five years but less than ten years —   — Greater than ten years 51,500   48,168 Total $ 569,748   $ 566,416 The following table summarizes the gross realized gains and losses related to sales of marketable securities (in thousands):   Three Months Ended   March 31,   2012   2011 Gross realized gains on sales $ 10,015   $ 3,697 Gross realized losses on sales $ (40,096 )   $ (1,362 ) The cost of securities sold was determined based on the specific identification method. The following table summarizes our available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in thousands):   Less Than 12 Months   12 Months or Greater   Total   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value March 31, 2012                       Debt securities:                       Certificates of deposit $ —   $ —   $ —   $ —   $ —   $ — Non-U.S. government securities —   —   —   —   —   — Corporate debt securities —   —   —   —   —   — Student loan-backed securities —   —   (3,332 )   48,168   (3,332 )   48,168 Total $ —   $ —   $ (3,332 )   $ 48,168   $ (3,332 )   $ 48,168 December 31, 2011                       Debt securities:                       Certificates of deposit $ (18 )   $ 1,019,982   $ —   $ —   $ (18 )   $ 1,019,982 Non-U.S. government securities (30,505 )   24,741   —   —   (30,505 )   24,741 Corporate debt securities (5 )   224,989   —   —   (5 )   224,989 Student loan-backed securities —   —   (4,548 )   46,952   (4,548 )   46,952 Total $ (30,528 )   $ 1,269,712   $ (4,548 )   $ 46,952   $ (35,076 )   $ 1,316,664 As of March 31, 2012 and December 31, 2011, we held a total of 12 and 42 securities, respectively, that were in an unrealized loss position.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet11.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments	3 Months Ended
Mar. 31, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	DERIVATIVE FINANCIAL INSTRUMENTS We operate in foreign countries, which exposes us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the Euro. In order to manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward and option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. We work only with major banks and closely monitor current market conditions, which limits the risk that counterparties to our contracts may be unable to perform. We also limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrecognized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes, nor do we hedge our net investment in any of our foreign subsidiaries. We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities of our foreign subsidiaries that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense), net on our Condensed Consolidated Statements of Income. We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturity dates of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess prospective hedge effectiveness using a regression analysis which calculates the change in cash flow as a result of the hedge instrument. On a monthly basis, we assess retrospective hedge effectiveness using a dollar offset approach. We exclude time value from our effectiveness testing and recognize changes in the time value of the hedge in other income (expense), net. The effective component of our hedge is recorded as an unrealized gain or loss on the hedging instrument in accumulated other comprehensive income (OCI) within stockholders’ equity. When the hedged forecasted transaction occurs, the hedge is de-designated and the unrealized gains or losses are reclassified into product sales. The majority of gains and losses related to the hedged forecasted transactions reported in accumulated OCI at March 31, 2012 will be reclassified to product sales within 12 months. We had notional amounts on foreign currency exchange contracts outstanding of $3.90 billion and $4.03 billion at March 31, 2012 and December 31, 2011, respectively. The following table summarizes information about the fair values of derivative instruments on our Condensed Consolidated Balance Sheets (in thousands):   March 31, 2012   Asset Derivatives   Liability Derivatives   Classification   Fair Value   Classification   Fair Value Derivatives designated as hedges:               Foreign currency exchange contracts Other current assets   $ 47,498   Other accrued liabilities   $ 14,564 Foreign currency exchange contracts Other noncurrent assets   4,459   Other long-term obligations   3,778 Total derivatives designated as hedges     51,957       18,342 Derivatives not designated as hedges:               Foreign currency exchange contracts Other current assets   1   Other accrued liabilities   61 Total derivatives not designated as hedges     1       61 Total derivatives     $ 51,958       $ 18,403     December 31, 2011   Asset Derivatives   Liability Derivatives   Classification   Fair Value   Classification   Fair Value Derivatives designated as hedges:               Foreign currency exchange contracts Other current assets   $ 77,066   Other accrued liabilities   $ 5,052 Foreign currency exchange contracts Other noncurrent assets   23,169   Other long-term obligations   620 Total derivatives designated as hedges     100,235       5,672 Derivatives not designated as hedges:               Foreign currency exchange contracts Other current assets   240   Other accrued liabilities   38 Total derivatives not designated as hedges     240       38 Total derivatives     $ 100,475       $ 5,710 The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Statements of Income (in thousands):   Three Months Ended   March 31,   2012   2011 Derivatives designated as hedges:       Net gains (losses) recognized in OCI (effective portion) $ (48,886 )   $ (127,499 ) Net gains (losses) reclassified from accumulated OCI into product sales (effective portion) $ 11,227   $ 9,929 Net gains (losses) recognized in other income (expense), net (ineffective portion and amounts excluded from effectiveness testing) $ (3,212 )   $ 995 Derivatives not designated as hedges:       Net gains (losses) recognized in other income (expense), net $ (27,174 )   $ (85,846 ) There were no material amounts recorded in other income (expense), net, for the three months ended March 31, 2012 and 2011 as a result of the discontinuance of cash flow hedges.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet12.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc.	3 Months Ended
Mar. 31, 2012
Business Combinations [Abstract]
Acquisition of Pharmasset, Inc.	ACQUISITION OF PHARMASSET, INC. On January 17, 2012, we completed the acquisition of Pharmasset, a publicly-held clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus was the development of oral therapeutics for the treatment of HCV infection. We believe the acquisition of Pharmasset will provide us with an opportunity to complement our existing HCV portfolio and help advance our effort to develop all-oral regimens for the treatment of HCV. We acquired all of the outstanding shares of common stock of Pharmasset for $137 per share in cash through a tender offer and subsequent merger under the terms of an agreement and plan of merger entered into in November 2011. The aggregate cash payment to acquire all of the outstanding shares of common stock was $11.1 billion. We financed the transaction with approximately $5.2 billion in cash on hand, $2.2 billion in bank debt issued in January 2012 and $3.7 billion in senior unsecured notes issued in December 2011. Pharmasset's lead compound, now known as GS-7977, is a nucleotide analog being evaluated in Phase 2 and Phase 3 clinical studies for the treatment of HCV infection across genotypes. Since the acquisition, we have received data from clinical trials evaluating GS-7977. For example: • In February 2012, we announced that data indicates that a 12 week course of treatment of GS-7977 with ribavirin in genotype 1 patients with a prior “null” response to an interferon-containing regimen will not be sufficient to cure their disease. • In April 2012, we announced data from our ELECTRON and QUANTUM studies, which found that 88% and 59% of genotype 1 patients and treatment-naïve patients, respectively, taking a 12-week all-oral regimen of GS-7977 and ribavirin achieved a sustained viral response four weeks after the completion of a 12-week course of therapy. We also announced data from our ATOMIC study, which found that 90% of genotype 1 HCV patients achieved a sustained viral response 12 weeks after a 12-week course of therapy with GS-7977 plus ribavirin and interferon.  • Also in April 2012, Bristol-Myers Squibb Company (BMS) also announced data from its Phase 2 study evaluating GS-7977 in combination with daclatasvir with and without ribavirin in genotype 1 and genotype 2 and 3 treatment-naïve infected patients. The data showed that 100% of genotype 1 and 91% of genotype 2 and 3 patients achieved a sustained viral response four weeks after the completion of a 24-week course of treatment. The Pharmasset acquisition was accounted for as a business combination. The results of operations of Pharmasset have been included in our Condensed Consolidated Statement of Income since January 13, 2012, the date on which we acquired approximately 88% of the outstanding shares of common stock of Pharmasset, cash consideration was transferred, and as a result, we obtained effective control of Pharmasset. During the first quarter of 2012, Pharmasset was integrated into Gilead's operations. As we do not track earnings results by product candidate or therapeutic area, we do not maintain separate earnings results for Pharmasset. The acquisition was completed on January 17, 2012, at which time Pharmasset became a wholly-owned subsidiary of Gilead. The following table summarizes the components of the cash paid to acquire Pharmasset (in thousands): Total consideration transferred $ 10,858,372 Stock-based compensation expense 193,937 Total cash paid $ 11,052,309 The $11.1 billion cash payment consisted of a $10.38 billion cash payment to the outstanding common stockholders as well as a $668.3 million cash payment to option holders under the Pharmasset stock option plans. The $10.38 billion cash payment to the outstanding common stockholders and $474.3 million of the cash payment to the option holders under the Pharmasset stock option plans were accounted for as consideration transferred. The remaining $193.9 million of cash payment was accounted for as stock-based compensation expense resulting from the accelerated vesting of Pharmasset employee options immediately prior to the acquisition. The following table summarizes the allocation of the consideration transferred to the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Intangible assets - in-process research and development $ 10,720,000 Cash and cash equivalents 106,737 Other assets acquired (liabilities assumed), net (43,182 ) Total identifiable net assets 10,783,555 Goodwill 74,817 Total consideration transferred $ 10,858,372 In-Process Research and Development (IPR&D) The estimated fair value of the acquired IPR&D related to GS-7977 was $10.72 billion, which was determined using a probability-weighted income approach, that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of 12%, which is based on the estimated weighted-average cost of capital for companies with profiles similar to that of Pharmasset. This rate is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the intangible asset. The projected cash flows from GS-7977 were based on key assumptions such as: the time and resources needed to complete its development considering its stage of development on the acquisition date, the probability of obtaining approval from the U.S. Food and Drug Administration (FDA) and other regulatory agencies, estimates of revenues and operating profits, the life of the potential commercialized product and other associated risks related to the viability of and potential alternative treatments in future target markets. Intangible assets related to IPR&D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&D efforts. Goodwill The $74.8 million of goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed and is attributable to the synergies expected from combining our R&D operations with Pharmasset's. None of the goodwill is expected to be deductible for income tax purposes. Stock-Based Compensation Expense The stock-based compensation expense recognized for the accelerated vesting of employee options immediately prior to the acquisition was reported in our Condensed Consolidated Statement of Income as follows (in thousands): Research and development expense $ 100,149 Selling, general and administrative expense 93,788 Total stock-based compensation expense $ 193,937 Other Costs Other costs incurred in connection with the acquisition include (in thousands):   Three Months Ended   March 31, 2012   December 31, 2011 Transaction costs (e.g. investment advisory, legal and accounting fees) $ 9,040   $ 28,461 Bridge financing costs 7,333   23,817 Restructuring costs 8,343   — Total other costs $ 24,716   $ 52,278 The following table summarizes these costs by the line item in the Condensed Consolidated Statement of Income in which these costs were recognized (in thousands).   Three Months Ended   March 31, 2012   December 31, 2011 Research and development expense $ 5,557   $ — Selling, general and administrative expense 11,826   28,461 Interest expense 7,333   23,817 Total other costs $ 24,716   $ 52,278 Pro Forma Information The following unaudited pro forma information presents the combined results of operations of Gilead and Pharmasset as if the acquisition of Pharmasset had been completed on January 1, 2011, with adjustments to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the operations of Gilead and Pharmasset. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands):   Three Months Ended   March 31,   2012   2011 Total revenues $ 2,282,449   $ 1,926,094 Net income attributable to Gilead $ 574,375   $ 397,165 The unaudited pro forma consolidated results include the following non-recurring pro forma adjustments: • Stock-based compensation expense of $193.9 million and other costs of $16.4 million were excluded from the net income attributable to Gilead for the three months ended March 31, 2012 and were included in the net income attributable to Gilead for the three months ended March 31, 2011; • Other costs of $52.3 million incurred during the three months ended December 31, 2011 were included in the net income attributable to Gilead for the three months ended March 31, 2011.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet13.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories	3 Months Ended
Mar. 31, 2012
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories are summarized as follows (in thousands):   March 31, 2012   December 31, 2011 Raw materials $ 584,835   $ 697,621 Work in process 603,428   466,499 Finished goods 229,770   225,863 Total $ 1,418,033   $ 1,389,983 As of March 31, 2012 and December 31, 2011, we held $974.3 million and $995.7 million of efavirenz in inventory, which was purchased from BMS at BMS’s estimated net selling price of efavirenz.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet14.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets	3 Months Ended
Mar. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	INTANGIBLE ASSETS AND GOODWILL The following table summarizes the carrying amount of our intangible assets and goodwill (in thousands):   March 31, 2012   December 31, 2011 Indefinite-lived intangible assets $ 10,986,200   $ 266,200 Finite-lived intangible assets 780,827   796,664 Total intangible assets 11,767,027   1,062,864 Goodwill 1,078,919   1,004,102 Total intangible assets and goodwill $ 12,845,946   $ 2,066,966 Indefinite-Lived Intangible Assets In January 2012, we acquired $10.72 billion of purchased IPR&D as part of our acquisition of Pharmasset that we have classified as indefinite-lived intangible assets (See Note 5). As of December 31, 2011, we had indefinite-lived intangible assets of $266.2 million, which consisted of $117.0 million and $149.2 million of purchased IPR&D from our acquisitions of Arresto Biosciences, Inc. and Calistoga Pharmaceuticals, Inc., respectively. Finite-Lived Intangible Assets The following table summarizes our finite-lived intangible assets (in thousands):   March 31, 2012   December 31, 2011   Gross Carrying Amount   Accumulated Amortization   Gross Carrying Amount   Accumulated Amortization Intangible asset - Ranexa $ 688,400   $ 106,104   $ 688,400   $ 97,099 Intangible asset - Lexiscan 262,800   76,159   262,800   69,723 Other 24,995   13,105   24,995   12,709 Total $ 976,195   $ 195,368   $ 976,195   $ 179,531 Amortization expense related to intangible assets was $15.8 million and $17.4 million for the three months ended March 31, 2012 and 2011, respectively, and was recorded in cost of goods sold in our Condensed Consolidated Statements of Income. As of March 31, 2012, the estimated future amortization expense associated with our intangible assets for the remaining nine months of 2012 and each of the five succeeding fiscal years are as follows (in thousands): Fiscal Year Amount 2012 (remaining nine months) $ 47,509 2013 64,283 2014 66,735 2015 73,261 2016 100,048 2017 132,786 Total $ 484,622 Goodwill The following table summarizes the changes in the carrying amount of goodwill (in thousands): Balance at December 31, 2011 $ 1,004,102 Goodwill resulting from the acquisition of Pharmasset 74,817 Balance at March 31, 2012 $ 1,078,919

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet15.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Collaborative Arrangements	3 Months Ended
Mar. 31, 2012
Collaborative Arrangements [Abstract]
Collaborative Arrangements	COLLABORATIVE ARRANGEMENTS From time to time, as a result of entering into strategic collaborations, we may hold investments in non-public companies. We review our interests in investee companies for consolidation and/or appropriate disclosure based on applicable guidance. Contractual terms which provide us control over an entity may require us to consolidate the entity. Entities consolidated because they are controlled by means other than a majority voting interest are referred to as variable interest entities (VIE). We assess whether we are the primary beneficiary of a VIE based on our power to direct the activities of the VIE that most significantly impact the VIE's economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. As of March 31, 2012, we determined that certain of our investee companies are VIEs; however, other than with respect to our joint ventures with BMS, we are not the primary beneficiary and therefore do not consolidate these investees. Bristol-Myers Squibb Company North America In 2004, we entered into a collaboration arrangement with BMS in the United States to develop and commercialize a single-tablet regimen containing our Truvada and BMS's Sustiva (efavirenz), which we sell as Atripla. The collaboration is structured as a joint venture and operates as a limited liability company named Bristol-Myers Squibb & Gilead Sciences, LLC, which we consolidate. The ownership interests of the joint venture and thus the sharing of product revenue and costs reflect the respective economic interests of BMS and Gilead and are based on the proportions of the net selling price of Atripla attributable to efavirenz and Truvada. Since the net selling price for Truvada may change over time relative to the net selling price of efavirenz, both BMS's and our respective economic interests in the joint venture may vary annually. We and BMS share marketing and sales efforts, with both parties providing equivalent sales force efforts at levels agreed to annually by BMS and Gilead. Since the second quarter of 2011, except for a limited number of activities that will be jointly managed, the parties no longer coordinate detailing and promotional activities in the United States and the parties have begun to reduce their joint promotional efforts in Canada as we launched Complera and in anticipation of the launch of Quad. The parties will continue to collaborate on activities such as manufacturing, regulatory, compliance and pharmacovigilance. We are responsible for accounting, financial reporting, tax reporting, manufacturing and product distribution for the joint venture. Both parties provide their respective bulk active pharmaceutical ingredients to the joint venture at their approximate market values. In 2006, we and BMS amended the joint venture's collaboration agreement to allow the joint venture to sell Atripla into Canada. As of March 31, 2012 and December 31, 2011, the joint venture held efavirenz active pharmaceutical ingredient which it purchased from BMS at BMS's estimated net selling price of efavirenz in the U.S. market. These amounts are included in inventories on our Condensed Consolidated Balance Sheets. As of March 31, 2012, total assets held by the joint venture were $1.70 billion and consisted primarily of cash and cash equivalents of $204.7 million, accounts receivable (including intercompany receivables with Gilead) of $278.1 million and inventories of $1.20 billion; total liabilities were $1.56 billion and consisted primarily of accounts payable (including intercompany payables with Gilead) of $611.7 million and other accrued expenses of $284.3 million. As of December 31, 2011, total assets held by the joint venture were $1.62 billion and consisted primarily of cash and cash equivalents of $156.9 million, accounts receivable (including intercompany receivables with Gilead) of $266.5 million and inventories of $1.19 billion; total liabilities were $1.27 billion and consisted primarily of accounts payable (including intercompany payables with Gilead) of $561.1 million and other accrued expenses of $232.9 million. These asset and liability amounts do not reflect the impact of intercompany eliminations that are included in our Condensed Consolidated Balance Sheets. Although we are the primary beneficiary of the joint venture, the legal structure of the joint venture limits the recourse that its creditors will have over our general credit or assets. Europe In 2007, Gilead Sciences Limited, a wholly-owned subsidiary in Ireland, and BMS entered into a collaboration arrangement to commercialize and distribute Atripla in the European Union, Iceland, Liechtenstein, Norway and Switzerland (collectively, the European Territory). The parties formed a limited liability company which we consolidate, to manufacture Atripla for distribution in the European Territory using efavirenz that it purchases from BMS at BMS's estimated net selling price of efavirenz in the European Territory. We are responsible for product distribution, inventory management and warehousing. Through our local subsidiaries, we have primary responsibility for order fulfillment, collection of receivables, customer relations and handling of sales returns in all the territories where we co-promote Atripla with BMS. Starting in 2012, except for a limited number of activities that will be jointly managed, the parties no longer coordinate detailing and promotional activities in the region. We are also responsible for accounting, financial reporting and tax reporting for the collaboration. As of March 31, 2012 and December 31, 2011, efavirenz purchased from BMS at BMS's estimated net selling price of efavirenz in the European Territory is included in inventories on our Condensed Consolidated Balance Sheets. The parties also formed a limited liability company to hold the marketing authorization for Atripla in Europe. We have primary responsibility for regulatory activities and we share marketing and sales efforts with BMS. In the major market countries, both parties have agreed to provide equivalent sales force efforts. Revenue and cost sharing is based on the relative ratio of the respective net selling prices of Truvada and efavirenz.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet16.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations	3 Months Ended
Mar. 31, 2012
Debt Disclosure [Abstract]
Long-Term Obligations [Text Block]	LONG-TERM OBLIGATIONS Financing Arrangements The following table summarizes the carrying amount of our borrowings under various financing arrangements (in thousands): Type of Borrowing Description Issue Date Due Date Interest Rate March 31, 2012   December 31, 2011 Convertible Senior May 2013 Notes April 2006 May 2013 0.625% $ 614,791   $ 607,036 Convertible Senior May 2014 Notes July 2010 May 2014 1.00% 1,188,594   1,181,525 Convertible Senior May 2016 Notes July 2010 May 2016 1.625% 1,138,538   1,132,293 Senior Unsecured April 2021 Notes March 2011 April 2021 4.50% 992,280   992,066 Senior Unsecured December 2014 Notes December 2011 December 2014 2.40% 749,157   749,078 Senior Unsecured December 2016 Notes December 2011 December 2016 3.05% 698,921   698,864 Senior Unsecured December 2021 Notes December 2011 December 2021 4.40% 1,247,212   1,247,138 Senior Unsecured December 2041 Notes December 2011 December 2041 5.65% 997,753   997,734 Term Loan Facility Term Loan January 2012 January 2015 Variable 650,000   — Credit Facility Short-Term Revolver January 2012 January 2013 Variable 400,000   — Credit Facility Five-Year Revolver January 2012 January 2017 Variable 750,000   — Total debt, net         $ 9,427,246   $ 7,605,734 Less current portion         1,350,000   — Total long-term debt, net         $ 8,077,246   $ 7,605,734 Credit Facilities We were eligible to borrow up to an aggregate of $1.25 billion in revolving credit loans under an amended and restated credit agreement that we entered into in 2007. The credit agreement also included a sub-facility for swing-line loans and letters of credit. As of December 31, 2011, we had $4.0 million in letters of credit outstanding under the credit agreement. In January 2012, we fully repaid the outstanding obligations under this credit agreement and terminated the credit agreement. In January 2012, in conjunction with our acquisition of Pharmasset, we entered into a five-year $1.25 billion revolving credit facility credit agreement (the Five-Year Revolving Credit Agreement), a $750.0 million short-term revolving credit facility credit agreement (the Short-Term Revolving Credit Agreement) and a $1.00 billion term loan facility (the Term Loan Credit Agreement). We borrowed $750.0 million under the Five-Year Revolving Credit Agreement, $400.0 million under the Short-Term Revolving Credit Agreement and $1.00 billion under the Term Loan Credit Agreement, upon the close of the acquisition. In March 2012, we repaid $350.0 million of the outstanding debt under the Term Loan Credit Agreement. All three credit agreements contain customary representations, warranties, affirmative, negative and financial maintenance covenants and events of default. The loans bear interest at either (i) the Eurodollar Rate plus the Applicable Margin or (ii) the Base Rate plus the Applicable Margin, each as defined in the applicable credit agreement. We may reduce the commitments and may prepay loans under any of these agreements in whole or in part at any time without premium or penalty. The Five-Year Revolving Credit Agreement was inclusive of a $30.0 million swing line loan sub-facility and a $25.0 million letter of credit sub-facility. As of March 31, 2012, we had $4.0 million in letters of credit outstanding under the Five-Year Revolving Credit Agreement. The Five-Year Revolving Credit Agreement will terminate and all unpaid borrowings thereunder shall be due and payable in January 2017. The Short-Term Revolving Credit Agreement will terminate and all unpaid borrowings thereunder shall be due and payable in January 2013; however, at our request, the maturity date may be extended until January 2014. All principal repayment installments under the Term Loan Credit Agreement will be due and payable as specified in the Term Loan Credit Agreement, with the final principal installment payment due and payable in January 2015.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet17.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Commitments And Contingencies	3 Months Ended
Mar. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings In June 2011, we received a subpoena from the United States Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices, of Atripla, Emtriva, Hepsera, Letairis, Truvada, Viread and Complera. We have been cooperating and will continue to cooperate with this governmental inquiry. An estimate of a possible loss or range of losses cannot be determined given we are at the early stage of the inquiry. We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that any of these legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet18.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation Expenses	3 Months Ended
Mar. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expenses	STOCK-BASED COMPENSATION EXPENSE The following table summarizes the stock-based compensation expense included in our Condensed Consolidated Statements of Income (in thousands):   Three Months Ended   March 31,   2012   2011 Cost of goods sold $ 2,101   $ 2,644 Research and development expenses 118,622   16,720 Selling, general and administrative expenses 121,945   30,106 Stock-based compensation expense included in total costs and expenses 242,668   49,470 Income tax effect (13,064 )   (12,856 ) Stock-based compensation expense, net of tax $ 229,604   $ 36,614 Total stock-based compensation for the three months ended March 31, 2012, included $100.1 million and $93.8 million in research and development expenses and selling, general and administrative expenses, respectively, related to the acceleration of unvested stock options in connection with the acquisition of Pharmasset.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet19.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' Equity	3 Months Ended
Mar. 31, 2012
Equity [Abstract]
Stockholders' Equity	2. STOCKHOLDERS’ EQUITY Stock Repurchase Program During the three months ended March 31, 2012, we repurchased a total of $20.8 million or 0.4 million shares of common stock under our January 2011, three-year, $5.00 billion stock repurchase program.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet20.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information	3 Months Ended
Mar. 31, 2012
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION We operate in one business segment, which primarily focuses on the development and commercialization of human therapeutics for life threatening diseases. All products are included in one segment, because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. Product sales consisted of the following (in thousands):   Three Months Ended   March 31,   2012   2011 Antiviral products:       Atripla $ 887,596   $ 744,512 Truvada 758,263   673,111 Viread 191,693   168,395 Complera/Eviplera 52,180   — Hepsera 29,297   38,096 Emtriva 6,777   6,576 Total antiviral products 1,925,806   1,630,690 AmBisome 84,764   78,506 Letairis 87,288   62,174 Ranexa 83,201   68,293 Other products 27,283   23,915 Total product sales $ 2,208,342   $ 1,863,578 The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):    Three Months Ended   March 31,   2012   2011 Cardinal Health, Inc. 20 %   17 % McKesson Corp. 16 %   15 % AmerisourceBergen Corp. 11 %   13 %

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet21.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes	3 Months Ended
Mar. 31, 2012
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Our income tax rate of 34.6% for the three months ended March 31, 2012 differed from the U.S. federal statutory rate of 35% due primarily to tax credits and certain operating earnings from non-U.S subsidiaries that are considered indefinitely invested outside of the United States, partially offset by state taxes and the stock-based compensation expense related to the Pharmasset acquisition for which we received no tax benefit. We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be permanently reinvested. We file federal, state and foreign income tax returns in many jurisdictions in the United States and abroad. For federal income tax purposes, the statute of limitations is open for 2008 and onwards. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years. For California income tax purposes, the statute of limitations is open for 2002 and onwards. Our income tax returns are audited by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service (IRS) for the 2008 and 2009 tax years and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions. As of March 31, 2012, we believe that it is reasonably possible that our unrecognized tax benefits will not significantly change in the next 12 months as we do not expect to have clarification from the IRS and other tax authorities around any of our uncertain tax positions. We record liabilities related to uncertain tax positions in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We do not believe any of our uncertain tax positions will have a material adverse effect on our Condensed Consolidated Financial Statements, although an adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet22.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
Mar. 31, 2012
Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of Gilead Sciences, Inc. (Gilead, we or us) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, intangible assets, allowance for doubtful accounts, prepaid royalties, clinical trial accruals, our tax provision and stock-based compensation. We base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and our joint ventures with Bristol-Myers Squibb Company (BMS), for which we are the primary beneficiary. We record a noncontrolling interest in our Condensed Consolidated Financial Statements to reflect BMS’s interest in the joint ventures. All intercompany transactions have been eliminated. The Condensed Consolidated Financial Statements include the results of companies acquired by us from the date of each acquisition for the applicable reporting periods. The accompanying Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2011, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC). Certain amounts within our Condensed Consolidated Balance Sheets have been reclassified to conform to the current presentation.
Earnings Per Share, Policy [Policy Text Block]	Net Income Per Share Attributable to Gilead Common Stockholders Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options, performance shares and the assumed exercise of warrants relating to the convertible senior notes due in May 2013 (May 2013 Notes), May 2014 (May 2014 Notes) and May 2016 (May 2016 Notes) (collectively, the Convertible Notes) are determined under the treasury stock method. Because the principal amount of the Convertible Notes will be settled in cash, only the conversion spread relating to the Convertible Notes is included in our calculation of diluted net income per share attributable to Gilead common stockholders. Our common stock resulting from the assumed settlement of the conversion spread of the Convertible Notes has a dilutive effect when the average market price of our common stock during the period exceeds the conversion prices of $38.10, $45.08 and $45.41 for the May 2013 Notes, May 2014 Notes and May 2016 Notes, respectively. In 2011, our convertible senior notes due in May 2011 (May 2011 Notes) matured and the related warrants expired and as a result, we have only considered their impact for the period they were outstanding on our net income per share calculations. Our common stock resulting from the assumed settlement of the conversion spread of the May 2011 Notes had a dilutive effect when the average market price of our common stock during the period exceeded the conversion price of $38.75. During the three months ended March 31, 2011, the average market price of our common stock exceeded the conversion price of the May 2011 Notes and the dilutive effect is included in the accompanying table. Warrants related to the May 2011 Notes had a dilutive effect when the average market price of our common stock during the period exceeded the warrants’ exercise price of $50.80. The average market price of our common stock during the three months ended March 31, 2011 did not exceed the warrants’ exercise price related to the May 2011 Notes; therefore, these warrants did not have a dilutive effect on our net income per share for that period. During the three months ended March 31, 2012, the average market price of our common stock exceeded the conversion prices of the May 2013 Notes, May 2014 Notes and May 2016 Notes and the dilutive effects are included in the accompanying table. During the three months ended March 31, 2011, the average market price of our common stock exceeded the conversion price of the May 2013 Notes and the dilutive effect is included in the accompanying table. During the three months ended March 31, 2011, the average market price of our common stock did not exceed the conversion prices of the May 2014 Notes and May 2016 Notes and therefore, these notes did not have a dilutive effect on our net income per share for that period. Warrants relating to the May 2013 Notes, May 2014 Notes and May 2016 Notes have a dilutive effect when the average market price of our common stock during the period exceeds the warrants’ exercise prices of $53.90, $56.76 and $60.10, respectively. The average market prices of our common stock during each of the three months ended March 31, 2012 and 2011 did not exceed the warrants’ exercise prices relating to any of the Convertible Notes; therefore, these warrants did not have a dilutive effect on our net income per share for those periods. Stock options to purchase approximately 10.9 million and 22.1 million weighted-average shares of our common stock were outstanding during the three months ended March 31, 2012 and 2011, respectively, but were not included in the computation of diluted net income per share attributable to Gilead common stockholders because their effect was antidilutive. The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in thousands):   Three Months Ended   March 31,   2012   2011 Numerator:       Net income attributable to Gilead $ 441,956   $ 651,141 Denominator:       Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders 756,286   796,115 Effect of dilutive securities:       Stock options and equivalents 14,873   15,007 Conversion spread related to the May 2011 Notes —   224 Conversion spread related to the May 2013 Notes 3,423   511 Conversion spread related to the May 2014 Notes 1,505   — Conversion spread related to the May 2016 Notes 1,301   — Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders 777,388   811,857
Concentration of Risk [Policy Text Block]	Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. The majority of our trade accounts receivable arises from product sales in the United States and Europe. As of March 31, 2012, our accounts receivable in Southern Europe, specifically Greece, Italy, Portugal and Spain, totaled approximately $1.25 billion, of which $719.5 million were greater than 120 days past due and $313.3 million were greater than 365 days past due. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowance for doubtful accounts was adequate at March 31, 2012.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements during the three months ended March 31, 2012 that are of significance to us.

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet23.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary Of Significant Accounting Policies (Tables)	3 Months Ended
Mar. 31, 2012
Accounting Policies [Abstract]
Reconciliation Of The Numerator And Denominator Used In The Calculation Of Basic And Diluted Net Income Per Share	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in thousands):   Three Months Ended   March 31,   2012   2011 Numerator:       Net income attributable to Gilead $ 441,956   $ 651,141 Denominator:       Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders 756,286   796,115 Effect of dilutive securities:       Stock options and equivalents 14,873   15,007 Conversion spread related to the May 2011 Notes —   224 Conversion spread related to the May 2013 Notes 3,423   511 Conversion spread related to the May 2014 Notes 1,505   — Conversion spread related to the May 2016 Notes 1,301   — Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders 777,388   811,857

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet24.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Tables)	3 Months Ended
Mar. 31, 2012
Fair Value Disclosures [Abstract]
Summary Of Assets And Liabilities Recorded At Fair Value	The following table summarizes, for assets or liabilities recorded at fair value, the respective fair value and the classification by level of input within the fair value hierarchy defined above (in thousands):   March 31, 2012   December 31, 2011   Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total Assets:                               Debt securities:                               Money market funds $ 518,248   $ —   $ —   $ 518,248   $ 7,455,982   $ —   $ —   $ 7,455,982 Certificates of deposit —   —   —   —   —   1,139,982   —   1,139,982 Non-U.S. government securities —   —   —   —   —   —   24,741   24,741 Corporate debt securities —   —   —   —   —   404,989   —   404,989 Student loan-backed securities —   —   48,168   48,168   —   —   46,952   46,952 Total debt securities 518,248   —   48,168   566,416   7,455,982   1,544,971   71,693   9,072,646 Equity securities —   —   —   —   8,503   —   —   8,503 Derivatives —   51,958   —   51,958   —   100,475   —   100,475   $ 518,248   $ 51,958   $ 48,168   $ 618,374   $ 7,464,485 $ 1,645,446 $ 71,693 $ 9,181,624 Liabilities:                               Contingent consideration $ —   $ —   $ 138,328   $ 138,328   $ —   $ —   $ 135,591   $ 135,591 Derivatives —   18,404   —   18,404   —   5,710   —   5,710   $ —   $ 18,404   $ 138,328   $ 156,732   $ —   $ 5,710   $ 135,591   $ 141,301
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of assets measured using Level 3 inputs (in thousands):     Three Months Ended   March 31,   2012   2011 Balance, beginning of period $ 71,693   $ 80,365 Total realized and unrealized gains (losses) included in:       Other income (expense), net (40,096 )   1,246 Other comprehensive income, net 33,094   2,160 Sales of marketable securities (16,523 )   (20,830 ) Transfers into Level 3 —   53,882 Balance, end of period $ 48,168   $ 116,823
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Text Block]	The following table provides a rollforward of our contingent consideration liabilities (in thousands):   Three Months Ended   March 31,   2012   2011 Balance, beginning of period $ 135,591   $ 11,100 Changes in valuation 2,737   — Balance, end of period $ 138,328   $ 11,100

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet25.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Tables)	3 Months Ended
Mar. 31, 2012
Investments, Debt and Equity Securities [Abstract]
Summary Of Available-For-Sale Debt And Equity Securities At Estimated Fair Value	The following table is a summary of available-for-sale debt and equity securities included in cash and cash equivalents or marketable securities in our Condensed Consolidated Balance Sheets. During the quarter ended March 31, 2012, we liquidated a portion of our investment portfolio to partially fund the acquisition of Pharmasset, Inc. (Pharmasset). Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services (in thousands):   Amortized Cost   Gross Unrealized Gains   Gross Unrealized Losses   Estimated Fair Value March 31, 2012               Debt securities:               Money market funds $ 518,248   $ —   $ —   $ 518,248 Certificates of deposit —   —   —   — Non-U.S. government securities —   —   —   — Corporate debt securities —   —   —   — Student loan-backed securities 51,500   —   (3,332 )   48,168 Total debt securities 569,748   —   (3,332 )   566,416 Equity securities —   —   —   — Total $ 569,748   $ —   $ (3,332 )   $ 566,416 December 31, 2011               Debt securities:               Money market funds $ 7,455,982   $ —   $ —   $ 7,455,982 Certificates of deposit 1,140,000   —   (18 )   1,139,982 Non-U.S. government securities 55,246   —   (30,505 )   24,741 Corporate debt securities 404,994   —   (5 )   404,989 Student loan-backed securities 51,500   —   (4,548 )   46,952 Total debt securities 9,107,722   —   (35,076 ) 9,072,646 Equity securities 1,451   7,052   —   8,503 Total $ 9,109,173   $ 7,052   $ (35,076 )   $ 9,081,149
Summary Of The Classification Of Available-For-Sale Debt And Equity Securities	The following table summarizes the classification of the available-for-sale debt and equity securities on our Condensed Consolidated Balance Sheets (in thousands):   March 31, 2012   December 31, 2011 Cash and cash equivalents $ 518,248   $ 9,000,954 Short-term marketable securities —   16,491 Long-term marketable securities 48,168   63,704 Total $ 566,416   $ 9,081,149
Summary Of Available-For-Sale Debt Securities By Contractual Maturity	The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):   March 31, 2012   Amortized Cost   Fair Value Less than one year $ 518,248   $ 518,248 Greater than one year but less than five years —   — Greater than five years but less than ten years —   — Greater than ten years 51,500   48,168 Total $ 569,748   $ 566,416
Summary Of Gross Realized Gains And Losses Related To Sales Of Marketable Securities	The following table summarizes the gross realized gains and losses related to sales of marketable securities (in thousands):   Three Months Ended   March 31,   2012   2011 Gross realized gains on sales $ 10,015   $ 3,697 Gross realized losses on sales $ (40,096 )   $ (1,362 )
Summary Of Available-For-Sale Debt Securities In A Continuous Unrealized Loss Position Deemed Not To Be Other-Than-Temporarily Impaired	The following table summarizes our available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in thousands):   Less Than 12 Months   12 Months or Greater   Total   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value March 31, 2012                       Debt securities:                       Certificates of deposit $ —   $ —   $ —   $ —   $ —   $ — Non-U.S. government securities —   —   —   —   —   — Corporate debt securities —   —   —   —   —   — Student loan-backed securities —   —   (3,332 )   48,168   (3,332 )   48,168 Total $ —   $ —   $ (3,332 )   $ 48,168   $ (3,332 )   $ 48,168 December 31, 2011                       Debt securities:                       Certificates of deposit $ (18 )   $ 1,019,982   $ —   $ —   $ (18 )   $ 1,019,982 Non-U.S. government securities (30,505 )   24,741   —   —   (30,505 )   24,741 Corporate debt securities (5 )   224,989   —   —   (5 )   224,989 Student loan-backed securities —   —   (4,548 )   46,952   (4,548 )   46,952 Total $ (30,528 )   $ 1,269,712   $ (4,548 )   $ 46,952   $ (35,076 )   $ 1,316,664

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet26.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Tables)	3 Months Ended
Mar. 31, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values Of Derivative Instruments On Condensed Consolidated Balance Sheets	The following table summarizes information about the fair values of derivative instruments on our Condensed Consolidated Balance Sheets (in thousands):   March 31, 2012   Asset Derivatives   Liability Derivatives   Classification   Fair Value   Classification   Fair Value Derivatives designated as hedges:               Foreign currency exchange contracts Other current assets   $ 47,498   Other accrued liabilities   $ 14,564 Foreign currency exchange contracts Other noncurrent assets   4,459   Other long-term obligations   3,778 Total derivatives designated as hedges     51,957       18,342 Derivatives not designated as hedges:               Foreign currency exchange contracts Other current assets   1   Other accrued liabilities   61 Total derivatives not designated as hedges     1       61 Total derivatives     $ 51,958       $ 18,403     December 31, 2011   Asset Derivatives   Liability Derivatives   Classification   Fair Value   Classification   Fair Value Derivatives designated as hedges:               Foreign currency exchange contracts Other current assets   $ 77,066   Other accrued liabilities   $ 5,052 Foreign currency exchange contracts Other noncurrent assets   23,169   Other long-term obligations   620 Total derivatives designated as hedges     100,235       5,672 Derivatives not designated as hedges:               Foreign currency exchange contracts Other current assets   240   Other accrued liabilities   38 Total derivatives not designated as hedges     240       38 Total derivatives     $ 100,475       $ 5,710
Summary Of The Effect Of Foreign Currency Exchange Contracts On Condensed Consolidated Statements Of Income	The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Statements of Income (in thousands):   Three Months Ended   March 31,   2012   2011 Derivatives designated as hedges:       Net gains (losses) recognized in OCI (effective portion) $ (48,886 )   $ (127,499 ) Net gains (losses) reclassified from accumulated OCI into product sales (effective portion) $ 11,227   $ 9,929 Net gains (losses) recognized in other income (expense), net (ineffective portion and amounts excluded from effectiveness testing) $ (3,212 )   $ 995 Derivatives not designated as hedges:       Net gains (losses) recognized in other income (expense), net $ (27,174 )   $ (85,846 )

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet27.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions of Pharmasset, Inc. (Tables)	3 Months Ended
Mar. 31, 2012
Business Combinations [Abstract]
Cash Paid in Acquisition [Table Text Block]	The following table summarizes the components of the cash paid to acquire Pharmasset (in thousands): Total consideration transferred $ 10,858,372 Stock-based compensation expense 193,937 Total cash paid $ 11,052,309
Fair Values Of The Assets Acquired And Liabilities Assumed	The following table summarizes the allocation of the consideration transferred to the acquisition date fair values of assets acquired and liabilities assumed (in thousands): Intangible assets - in-process research and development $ 10,720,000 Cash and cash equivalents 106,737 Other assets acquired (liabilities assumed), net (43,182 ) Total identifiable net assets 10,783,555 Goodwill 74,817 Total consideration transferred $ 10,858,372
Accelerated Stock-Based Compensation Expense [Table Text Block]	The stock-based compensation expense recognized for the accelerated vesting of employee options immediately prior to the acquisition was reported in our Condensed Consolidated Statement of Income as follows (in thousands): Research and development expense $ 100,149 Selling, general and administrative expense 93,788 Total stock-based compensation expense $ 193,937
Other Transaction Costs [Table Text Block]	Other costs incurred in connection with the acquisition include (in thousands):   Three Months Ended   March 31, 2012   December 31, 2011 Transaction costs (e.g. investment advisory, legal and accounting fees) $ 9,040   $ 28,461 Bridge financing costs 7,333   23,817 Restructuring costs 8,343   — Total other costs $ 24,716   $ 52,278
Other Transaction Costs Classified by Expense Category [Table Text Block]	The following table summarizes these costs by the line item in the Condensed Consolidated Statement of Income in which these costs were recognized (in thousands).   Three Months Ended   March 31, 2012   December 31, 2011 Research and development expense $ 5,557   $ — Selling, general and administrative expense 11,826   28,461 Interest expense 7,333   23,817 Total other costs $ 24,716   $ 52,278
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information presents the combined results of operations of Gilead and Pharmasset as if the acquisition of Pharmasset had been completed on January 1, 2011, with adjustments to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the operations of Gilead and Pharmasset. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands):   Three Months Ended   March 31,   2012   2011 Total revenues $ 2,282,449   $ 1,926,094 Net income attributable to Gilead $ 574,375   $ 397,165

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet28.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Tables)	3 Months Ended
Mar. 31, 2012
Inventory Disclosure [Abstract]
Schedule Of Inventories	Inventories are summarized as follows (in thousands):   March 31, 2012   December 31, 2011 Raw materials $ 584,835   $ 697,621 Work in process 603,428   466,499 Finished goods 229,770   225,863 Total $ 1,418,033   $ 1,389,983

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet29.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Tables)	3 Months Ended
Mar. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	The following table summarizes the carrying amount of our intangible assets and goodwill (in thousands):   March 31, 2012   December 31, 2011 Indefinite-lived intangible assets $ 10,986,200   $ 266,200 Finite-lived intangible assets 780,827   796,664 Total intangible assets 11,767,027   1,062,864 Goodwill 1,078,919   1,004,102 Total intangible assets and goodwill $ 12,845,946   $ 2,066,966
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]	The following table summarizes our finite-lived intangible assets (in thousands):   March 31, 2012   December 31, 2011   Gross Carrying Amount   Accumulated Amortization   Gross Carrying Amount   Accumulated Amortization Intangible asset - Ranexa $ 688,400   $ 106,104   $ 688,400   $ 97,099 Intangible asset - Lexiscan 262,800   76,159   262,800   69,723 Other 24,995   13,105   24,995   12,709 Total $ 976,195   $ 195,368   $ 976,195   $ 179,531
Estimated Future Amortization Expense	As of March 31, 2012, the estimated future amortization expense associated with our intangible assets for the remaining nine months of 2012 and each of the five succeeding fiscal years are as follows (in thousands): Fiscal Year Amount 2012 (remaining nine months) $ 47,509 2013 64,283 2014 66,735 2015 73,261 2016 100,048 2017 132,786 Total $ 484,622
Schedule of Goodwill [Table Text Block]	The following table summarizes the changes in the carrying amount of goodwill (in thousands): Balance at December 31, 2011 $ 1,004,102 Goodwill resulting from the acquisition of Pharmasset 74,817 Balance at March 31, 2012 $ 1,078,919

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet30.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Tables)	3 Months Ended
Mar. 31, 2012
Debt Disclosure [Abstract]
Schedule Of Carrying Amount Of Convertible Senior Notes	The following table summarizes the carrying amount of our borrowings under various financing arrangements (in thousands): Type of Borrowing Description Issue Date Due Date Interest Rate March 31, 2012   December 31, 2011 Convertible Senior May 2013 Notes April 2006 May 2013 0.625% $ 614,791   $ 607,036 Convertible Senior May 2014 Notes July 2010 May 2014 1.00% 1,188,594   1,181,525 Convertible Senior May 2016 Notes July 2010 May 2016 1.625% 1,138,538   1,132,293 Senior Unsecured April 2021 Notes March 2011 April 2021 4.50% 992,280   992,066 Senior Unsecured December 2014 Notes December 2011 December 2014 2.40% 749,157   749,078 Senior Unsecured December 2016 Notes December 2011 December 2016 3.05% 698,921   698,864 Senior Unsecured December 2021 Notes December 2011 December 2021 4.40% 1,247,212   1,247,138 Senior Unsecured December 2041 Notes December 2011 December 2041 5.65% 997,753   997,734 Term Loan Facility Term Loan January 2012 January 2015 Variable 650,000   — Credit Facility Short-Term Revolver January 2012 January 2013 Variable 400,000   — Credit Facility Five-Year Revolver January 2012 January 2017 Variable 750,000   — Total debt, net         $ 9,427,246   $ 7,605,734 Less current portion         1,350,000   — Total long-term debt, net         $ 8,077,246   $ 7,605,734

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet31.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation Expenses (Tables)	3 Months Ended
Mar. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule Of Stock-Based Compensation Expenses Included In Consolidated Statements Of Income	The following table summarizes the stock-based compensation expense included in our Condensed Consolidated Statements of Income (in thousands):   Three Months Ended   March 31,   2012   2011 Cost of goods sold $ 2,101   $ 2,644 Research and development expenses 118,622   16,720 Selling, general and administrative expenses 121,945   30,106 Stock-based compensation expense included in total costs and expenses 242,668   49,470 Income tax effect (13,064 )   (12,856 ) Stock-based compensation expense, net of tax $ 229,604   $ 36,614

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet32.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Tables)	3 Months Ended
Mar. 31, 2012
Segment Reporting [Abstract]
Product Sales	Product sales consisted of the following (in thousands):   Three Months Ended   March 31,   2012   2011 Antiviral products:       Atripla $ 887,596   $ 744,512 Truvada 758,263   673,111 Viread 191,693   168,395 Complera/Eviplera 52,180   — Hepsera 29,297   38,096 Emtriva 6,777   6,576 Total antiviral products 1,925,806   1,630,690 AmBisome 84,764   78,506 Letairis 87,288   62,174 Ranexa 83,201   68,293 Other products 27,283   23,915 Total product sales $ 2,208,342   $ 1,863,578
Schedule Of Revenues From Each Customer Who Individually Accounted For 10% Or More Of Total Revenues	The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):    Three Months Ended   March 31,   2012   2011 Cardinal Health, Inc. 20 %   17 % McKesson Corp. 16 %   15 % AmerisourceBergen Corp. 11 %   13 %

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet33.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary Of Significant Accounting Policies (Reconciliation Of The Numerator And Denominator Used In The Calculation Of Basic And Diluted Net Income Per Share) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income Attributable to Gilead	$ 441,956	$ 651,141
Weighted-average shares of common stock outstanding used in the calculation of basic net income per share attributable to Gilead common stockholders	756,286	796,115
Effect of dilutive securities, stock options and equivalents	14,873	15,007
Weighted-average shares of common stock outstanding used in the calculation of diluted net income per share attributable to Gilead common stockholders	777,388	811,857
May 2011 Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities, conversion spread	0	224
May 2013 Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities, conversion spread	3,423	511
Convertible Senior Notes Due In May 2014 Member
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities, conversion spread	1,505	0
Convertible Senior Notes Due In May 2016 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effect of dilutive securities, conversion spread	1,301	0

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet34.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $) Share data in Millions, except Per Share data, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Summary of Significant Accounting Policies [Line Items]
Weighted-average shares of common stock outstanding excluded from the computation of diluted net income per share because their effect was antidilutive	10.9	22.1
Total Southern European Accounts Receivable	$ 1,250,000,000
Total Southern European Accounts Receivable Greater Than 120 Days	719,500,000
Total Southern European Accounts Receivable Greater Than 365 Days	$ 313,300,000
May 2011 Notes [Member]
Summary of Significant Accounting Policies [Line Items]
Conversion price of notes	$ 38.75
Warrants exercise price	50.8
May 2013 Notes [Member]
Summary of Significant Accounting Policies [Line Items]
Conversion price of notes	$ 38.1
Warrants exercise price	53.9
May 2014 Notes [Member]
Summary of Significant Accounting Policies [Line Items]
Conversion price of notes	$ 45.08
Warrants exercise price	56.76
May 2016 Notes [Member]
Summary of Significant Accounting Policies [Line Items]
Conversion price of notes	$ 45.41
Warrants exercise price	60.1

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet35.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Summary Of Assets and Liabilities Recorded At Fair Value) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011	Mar. 31, 2011	Dec. 31, 2010
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	$ 566,416	$ 9,072,646
Equity securities	0	8,503
Derivatives, assets	51,958	100,475
Fair value, total	618,374	9,181,624
Contingent Consideration	138,328	135,591	11,100	11,100
Derivatives, liabilities	18,404	5,710
Fair value, total	156,732	141,301
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	518,248	7,455,982
Certificates of Deposit [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	1,139,982
Non-U.S. Government Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	24,741
Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	404,989
Student Loan-Backed Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	48,168	46,952
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	518,248	7,455,982
Equity securities	0	8,503
Derivatives, assets	0	0
Fair value, total	518,248	7,464,485
Contingent Consideration	0	0
Derivatives, liabilities	0	0
Fair value, total	0	0
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	518,248	7,455,982
Level 1 [Member] | Certificates of Deposit [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 1 [Member] | Non-U.S. Government Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 1 [Member] | Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 1 [Member] | Student Loan-Backed Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	1,544,971
Equity securities	0	0
Derivatives, assets	51,958	100,475
Fair value, total	51,958	1,645,446
Contingent Consideration	0	0
Derivatives, liabilities	18,404	5,710
Fair value, total	18,404	5,710
Level 2 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 2 [Member] | Certificates of Deposit [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	1,139,982
Level 2 [Member] | Non-U.S. Government Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	404,989
Level 2 [Member] | Student Loan-Backed Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	48,168	71,693
Equity securities	0	0
Derivatives, assets	0	0
Fair value, total	48,168	71,693
Contingent Consideration	138,328	135,591
Derivatives, liabilities	0	0
Fair value, total	138,328	135,591
Level 3 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 3 [Member] | Certificates of Deposit [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 3 [Member] | Non-U.S. Government Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	24,741
Level 3 [Member] | Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	0	0
Level 3 [Member] | Student Loan-Backed Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value, Debt securities	$ 48,168	$ 46,952

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet36.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Reconciliation Of Marketable Securities Measured At Fair Value Using Significant Unobservable Inputs (Level 3)) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issuances, Settlements [Abstract]
Balance, beginning of period	$ 71,693	$ 80,365
Total realized and unrealized gains (losses) included in, interest and other income, net	(40,096)	1,246
Total realized and unrealized gains (losses) included in other comprehensive income, net	33,094	2,160
Sales of marketable securities	(16,523)	(20,830)
Transfers into Level 3	0	53,882
Balance, end of period	$ 48,168	$ 116,823

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet37.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements Contingent Consideration Rollforward (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011	Dec. 31, 2011	Dec. 31, 2010
Fair Value Disclosures [Abstract]
Contingent Consideration, Balance at Period Start, End	$ 138,328	$ 11,100	$ 135,591	$ 11,100
Changes in Valuation	$ 2,737	$ 0

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet38.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012 April 2021 Senior Unsecured Notes [Member]	Dec. 31, 2011 April 2021 Senior Unsecured Notes [Member]	Mar. 31, 2011 April 2021 Senior Unsecured Notes [Member]	Mar. 31, 2012 Senior Unsecured Notes Due In December Two Thousand Fourteen December Two Thousand Sixteen December Two Thousand Twenty One December Two Thousand Forty One [Member]	Jan. 17, 2012 Senior Unsecured Notes Due In December Two Thousand Fourteen December Two Thousand Sixteen December Two Thousand Twenty One December Two Thousand Forty One [Member]	Dec. 31, 2011 Senior Unsecured Notes Due In December Two Thousand Fourteen December Two Thousand Sixteen December Two Thousand Twenty One December Two Thousand Forty One [Member]	Mar. 31, 2012 Convertible Notes Payable [Member]	Dec. 31, 2011 Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Carrying value, convertible notes									$ 2,940,000,000	$ 2,920,000,000
Carrying value, senior unsecured notes			992,300,000	992,100,000		3,690,000,000		3,690,000,000
Fair value, convertible notes									3,990,000,000	3,530,000,000
Fair Value, senior unsecures notes			1,060,000,000	1,060,000,000		3,890,000,000		3,930,000,000
Principal amount, senior unsecured notes					1,000,000,000		3,700,000,000	3,700,000,000
Weighted-average expected life of underlying student loans minimum, years	2
Weighted-average expected life of underlying student loans maximum, years	7
Annual discount rate used in discounted cash flow model	2.18%
Auction rate reset, lower range, in days	7
Auction rate reset, upper range, in days	14
Auction rate securities year of maturity, lower range	2025
Auction rate securities year of maturity, higher range	2040
Auction rate securities annual interest rate, lower range	0.12%
Auction rate securities annual interest rate, higher range	0.77%
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	$ (40,096,000)	$ 1,246,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet39.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary Of Available-For-Sale Debt And Equity Securities At Estimated Fair Value) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Total	$ 569,748	$ 9,109,173
Gross Unrealized Gains	0	7,052
Gross Unrealized Losses	3,332	35,076
Estimated Fair Value, Debt securities	566,416	9,072,646
Estimated Fair Value, Equity securities	0	8,503
Estimated Fair Value, Total	566,416	9,081,149
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Debt securities	518,248	7,455,982
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value, Debt securities	518,248	7,455,982
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Debt securities	0	1,140,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	18
Estimated Fair Value, Debt securities	0	1,139,982
Non-U.S. Government Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Debt securities	0	55,246
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	30,505
Estimated Fair Value, Debt securities	0	24,741
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Debt securities	0	404,994
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	5
Estimated Fair Value, Debt securities	0	404,989
Student Loan-Backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Debt securities	51,500	51,500
Gross Unrealized Gains	0	0
Gross Unrealized Losses	3,332	4,548
Estimated Fair Value, Debt securities	48,168	46,952
Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Debt securities	569,748	9,107,722
Gross Unrealized Gains	0	0
Gross Unrealized Losses	3,332	35,076
Estimated Fair Value, Debt securities	566,416	9,072,646
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost, Equity securities	0	1,451
Gross Unrealized Gains	0	7,052
Gross Unrealized Losses	0	0
Estimated Fair Value, Equity securities	$ 0	$ 8,503

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet40.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary Of The Classification Of Available-For-Sale Debt And Equity Securities) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 518,248	$ 9,000,954
Short-term marketable securities	0	16,491
Long-term marketable securities	48,168	63,704
Estimated Fair Value, Total	$ 566,416	$ 9,081,149

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet41.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary Of Available-For-Sale Debt Securities By Contractual Maturity) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Investments, Debt and Equity Securities [Abstract]
Less Than One Year	$ 518,248
Greater Than One Year But Less Than Five Years	0
Greater than five years but less than ten years, Amortized Cost	0
Greater than ten years, Amortized Cost	51,500
Total, Amortized Cost	569,748
Less than one year, Fair Value	518,248
Greater than one year but less than five years, Fair Value	0
Greater than five years but less than ten years, Fair Value	0
Greater than ten years, Fair Value	48,168
Total, Fair Value	$ 566,416	$ 9,072,646

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet42.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary Of Gross Realized Gains And Losses Related To Sales Of Marketable Securities) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Investments, Debt and Equity Securities [Abstract]
Gross Realized Gains on Sales	$ 10,015	$ 3,697
Gross Realized Losses on Sales	$ 40,096	$ 1,362

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet43.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Summary Of Available-For-Sale Debt Securities In A Continuous Unrealized Loss Position Deemed Not To Be Other-Than-Temporarily Impaired) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Gross Unrealized Losses	$ 0	$ 30,528
Less than 12 months, Estimated Fair Value	0	1,269,712
12 months or greater, Gross Unrealized Losses	3,332	4,548
12 months or greater, Estimated Fair Value	48,168	46,952
Total, Gross Unrealized Losses	3,332	35,076
Total, Estimated Fair Value	48,168	1,316,664
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Gross Unrealized Losses	0	18
Less than 12 months, Estimated Fair Value	0	1,019,982
12 months or greater, Gross Unrealized Losses	0	0
12 months or greater, Estimated Fair Value	0	0
Total, Gross Unrealized Losses	0	18
Total, Estimated Fair Value	0	1,019,982
Non-U.S. Government Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Gross Unrealized Losses	0	30,505
Less than 12 months, Estimated Fair Value	0	24,741
12 months or greater, Gross Unrealized Losses	0	0
12 months or greater, Estimated Fair Value	0	0
Total, Gross Unrealized Losses	0	30,505
Total, Estimated Fair Value	0	24,741
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Gross Unrealized Losses	0	5
Less than 12 months, Estimated Fair Value	0	224,989
12 months or greater, Gross Unrealized Losses	0	0
12 months or greater, Estimated Fair Value	0	0
Total, Gross Unrealized Losses	0	5
Total, Estimated Fair Value	0	224,989
Student Loan-Backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Gross Unrealized Losses	0	0
Less than 12 months, Estimated Fair Value	0	0
12 months or greater, Gross Unrealized Losses	3,332	4,548
12 months or greater, Estimated Fair Value	48,168	46,952
Total, Gross Unrealized Losses	3,332	4,548
Total, Estimated Fair Value	$ 48,168	$ 46,952

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet44.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Available-For-Sale Securities (Narrative) (Details)	Mar. 31, 2012	Dec. 31, 2011
Investments, Debt and Equity Securities [Abstract]
Number of Available-For-Sale Securities, Unrealized Loss Position	12	42

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet45.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Summary Of Information About The Fair Values Of Derivative Instruments On Condensed Consolidated Balance Sheets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	$ 51,958	$ 100,475
Derivative Liability, Fair Value	18,403	5,710
Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	51,957	100,235
Derivative Liability, Fair Value	18,342	5,672
Total Derivatives Not Designated As Hedges Member
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	1	240
Derivative Liability, Fair Value	61	38
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	47,498	77,066
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Other Noncurrent Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	4,459	23,169
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Other Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value	14,564	5,052
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member] | Other Long-Term Obligations [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value	3,778	620
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value	1	240
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member] | Other Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value	$ 61	$ 38

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet46.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Summary Of The Effect Of Foreign Currency Exchange Contracts On Condensed Consolidated Statements Of Income) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Net Gains (Losses) Recognized in OCI (Effective Portion)	$ (48,886)	$ (127,499)
Net Gains (Losses) Reclassified from Accumulated OCI into Product Sales (Effective Portion)	11,227	9,929
Net Losses Recognized in Interest and Other Income, Net (Ineffective Portion and Amounts Excluded from Effectiveness Testing)	(3,212)	995
Net Gains (Losses) Recognized in Interest and Other Income, Net	$ (27,174)	$ (85,846)

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet47.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Derivative Financial Instruments (Narrative) (Details) (USD $) In Billions, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional amounts on foreign currency exchange forward contracts outstanding	$ 3.9	$ 4.03

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet48.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc. Cash Consideration Paid in Acquisition (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Jan. 17, 2012
Business Combinations [Abstract]
Business Combination, Consideration Transferred	$ 10,858,372	$ 10,858,372
Accelerated Stock-Based Compensation	193,937
Business Acquisition, Cost of Acquired Entity, Cash Paid	$ 11,052,309	$ 11,100,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet49.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisitions (Fair Values Of The Assets Acquired And Liabilities Assumed) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Jan. 17, 2012
Business Combinations [Abstract]
IPR&D		$ 10,720,000
Cash and Cash Equivalents		106,737
Net Assets Acquired (Liabilities Assumed)		(43,182)
Total Identifiable Net Tangible Assets		10,783,555
Goodwill	74,817	74,817
Business Combination, Consideration Transferred	$ 10,858,372	$ 10,858,372

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet50.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc. Accelerated Stock-Based Compensation Expense (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012
Accelerated Stock-Based Compensation [Line Items]
Accelerated Stock-Based Compensation	$ 193,937
Research and Development Expense [Member]
Accelerated Stock-Based Compensation [Line Items]
Accelerated Stock-Based Compensation	100,149
Selling General And Administrative Expenses [Member]
Accelerated Stock-Based Compensation [Line Items]
Accelerated Stock-Based Compensation	$ 93,788

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet51.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc. Other Transaction Costs (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Dec. 31, 2011	Mar. 31, 2011
Business Combinations [Abstract]
Business Acquisition, Cost of Acquired Entity, Transaction Costs	$ 9,040	$ 28,461
Bridge Financing Costs Associated with Acquisition	7,333	23,817
Restructuring Charges	8,343	0
Other Costs Associated with Acquisition	$ 24,716	$ 52,278	$ 16,400

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet52.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc. Other Costs as Classifed by Expense Category (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Dec. 31, 2011	Mar. 31, 2011
Other Costs Classified by Expense Category [Line Items]
Other Costs Associated with Acquisition	$ 24,716	$ 52,278	$ 16,400
Research and Development Expense [Member]
Other Costs Classified by Expense Category [Line Items]
Other Costs Associated with Acquisition	5,557	0
Selling General And Administrative Expenses [Member]
Other Costs Classified by Expense Category [Line Items]
Other Costs Associated with Acquisition	11,826
Interest Expense [Member]
Other Costs Classified by Expense Category [Line Items]
Other Costs Associated with Acquisition	$ 7,333

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet53.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc. Table of Pro Forma of Pharmasset (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Business Combinations [Abstract]
Business Acquisition, Pro Forma Revenue	$ 2,282,449	$ 1,926,094
Business Acquisition, Pro Forma Net Income (Loss)	$ 574,375	$ 397,165

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet54.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Acquisition of Pharmasset, Inc. (Narrative) (Details) (USD $)	3 Months Ended
Mar. 31, 2012	Dec. 31, 2011	Mar. 31, 2011	Jan. 17, 2012	Jan. 13, 2012
Senior Notes Used in Acquisition[Line Items]
Per share acquisition price				$ 137
Total cash paid for acquisition	$ 11,052,309,000			$ 11,100,000,000
Acquisition financed with cash on hand				5,200,000,000
Bank Debt Used in Acquisition				2,200,000,000
Outstanding Common Stock Acquired					88.00%
Cash Payments to Outstanding Shareholders				10,380,000,000
Cash Payment to Option Holders				668,300,000
Payments to Outstanding Common Shareholders Treated as Consideration				474,300,000
Accelerated Stock-Based Compensation	193,937,000
IPR&D				10,720,000,000
Present value discount rate				12.00%
Goodwill resulting from acquisition	74,817,000			74,817,000
Other Costs Associated with Acquisition	24,716,000	52,278,000	16,400,000
Senior Unsecured Notes Due In December Two Thousand Fourteen December Two Thousand Sixteen December Two Thousand Twenty One December Two Thousand Forty One [Member]
Senior Notes Used in Acquisition[Line Items]
Debt Instrument, Face Amount		$ 3,700,000,000		$ 3,700,000,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet55.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Schedule Of Inventories) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Inventory Disclosure [Abstract]
Raw Materials	$ 584,835	$ 697,621
Work in Process	603,428	466,499
Finished Goods	229,770	225,863
Total	$ 1,418,033	$ 1,389,983

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet56.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Inventories (Narrative) (Details) (USD $) In Millions, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Inventory Disclosure [Abstract]
Portion of Inventory Specifically Related to a Drug Compound	$ 974.3	$ 995.7

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet57.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule Of Carrying Amount Of Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Indefinite lived intangible assets	$ 10,986,200	$ 266,200
Finite lived intangible assets	780,827	796,664
Intangible Assets, Net (Excluding Goodwill)	11,767,027	1,062,864
Goodwill	1,078,919	1,004,102
Total	$ 12,845,946	$ 2,066,966

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet58.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule Of Finite-Lived Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 780,827	$ 796,664
Ranexa [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	688,400	688,400
Accumulated Amortization	106,104	97,099
Lexiscan [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	262,800	262,800
Accumulated Amortization	76,159	69,723
Other [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	24,995	24,995
Accumulated Amortization	13,105	12,709
Total [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	976,195	976,195
Accumulated Amortization	$ 195,368	$ 179,531

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet59.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Estimated Future Amortization Expense) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
2012 (Remaining Nine Months)	$ 47,509
2013	64,283
2014	66,735
2015	73,261
2016	100,048
2017	132,786
Total	$ 484,622

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet60.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Jan. 17, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at December 31, 2011	$ 1,078,919		$ 1,004,102
Goodwill resulting from acquisition	74,817	74,817
Balance at March 31, 2012	$ 1,078,919		$ 1,004,102

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet61.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011	Dec. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 15,800,000	$ 17,400,000
Indefinite-lived intangible assets	10,986,200,000		266,200,000
IPR&D [Member] | Pharmasset [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	10,720,000,000
IPR&D [Member] | Arresto Biosciences Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets			117,000,000
IPR&D [Member] | Calistoga Pharmaceuticals Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets			$ 149,200,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet62.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Collaborative Arrangements (Details) (USD $)	Mar. 31, 2012	Dec. 31, 2011
Collaborative Arrangements [Abstract]
Total Assets Held by the Joint Venture	$ 1,700,000,000	$ 1,620,000,000
Cash and Cash Equivalents Held by Joint Venture	204,700,000	156,900,000
Accounts Receivable Held by Joint Venture	278,100,000	266,500,000
Inventories Held by Joint Venture	1,200,000,000	1,190,000,000
Total Liabilities Held by the Joint Venture	1,560,000,000	1,270,000,000
Acounts Payable Held by Joint Venture	611,700,000	561,100,000
Other Accrued Expenses Held by Joint Venture	$ 284,300,000	$ 232,900,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet63.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Schedule Of Carrying Amount Of Convertible Senior Notes) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Long-term Debt, net	$ 8,077,246	$ 7,605,734
Total Debt, Including Long-Term and Short-Term Portions	9,427,246	7,605,734
Long-term Debt, Current Maturities	1,350,000	0
Long-term Debt, Excluding Current Maturities	8,077,246	7,605,734
May 2013 Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	614,791	607,036
Debt Instrument, Interest Rate, Stated Percentage	0.63%
May 2014 Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	1,188,594	1,181,525
Debt Instrument, Interest Rate, Stated Percentage	1.00%
May 2016 Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	1,138,538	1,132,293
Debt Instrument, Interest Rate, Stated Percentage	1.63%
April 2021 Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	992,280	992,066
Debt Instrument, Interest Rate, Stated Percentage	4.50%
December 2014 Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	749,157	749,078
Debt Instrument, Interest Rate, Stated Percentage	2.40%
December 2016 Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	698,921	698,864
Debt Instrument, Interest Rate, Stated Percentage	3.05%
December 2021 Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	1,247,212	1,247,138
Debt Instrument, Interest Rate, Stated Percentage	4.40%
December 2041 Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, net	997,753	997,734
Debt Instrument, Interest Rate, Stated Percentage	5.65%
Term Loan Facility due January 2015 [Member]
Debt Instrument [Line Items]
Carrying amount of term loan facility	650,000	0
Credit Facility Due January 2013 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding	400,000	0
Credit Facility Due January 2017 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding	$ 750,000	$ 0

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet64.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Long-Term Obligations (Narrative) (Details) (USD $)	Mar. 31, 2012 January 2012 Five-Year Revolving Credit Agreement [Member]	Mar. 31, 2012 December 2007 Amended and Restated Credit Agreement [Member]	Dec. 31, 2011 December 2007 Amended and Restated Credit Agreement [Member]	Mar. 31, 2012 January 2012 Short Term Revolving Credit Agreement [Member]	Mar. 31, 2012 January 2012 Term Loan Credit Agreement [Member]	Mar. 31, 2012 January 2012 Swing Line Loan Sub Facility [Member]	Mar. 31, 2012 January 2012 Letter Of Credit Sub Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,250,000,000	$ 1,250,000,000		$ 750,000,000	$ 1,000,000,000	$ 30,000,000	$ 25,000,000
Line of Credit Facility, Amount Outstanding	750,000,000		4,000,000	400,000,000	1,000,000,000
Repayments of Debt					$ 350,000,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet65.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation Expenses (Schedule Of Stock-Based Compensation Expenses Included In Consolidated Statements Of Income) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Stock-Based Compensation Expenses included in Total Costs and Expenses	$ 242,668	$ 49,470
Income Tax Effect	(13,064)	(12,856)
Stock-Based Compensation Expense, Net of Tax	229,604	36,614
Cost Of Goods Sold [Member]
Stock-Based Compensation Expenses included in Total Costs and Expenses	2,101	2,644
Research And Development Expenses [Member]
Stock-Based Compensation Expenses included in Total Costs and Expenses	118,622	16,720
Selling General And Administrative Expenses [Member]
Stock-Based Compensation Expenses included in Total Costs and Expenses	$ 121,945	$ 30,106

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet66.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stock-Based Compensation Expenses Stock-Based Compensation Expenses (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012
Accelerated Stock-Based Compensation [Line Items]
Accelerated Stock-Based Compensation	$ 193,937
Selling General And Administrative Expenses [Member]
Accelerated Stock-Based Compensation [Line Items]
Accelerated Stock-Based Compensation	93,788
Research and Development Expense [Member]
Accelerated Stock-Based Compensation [Line Items]
Accelerated Stock-Based Compensation	$ 100,149

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet67.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Stockholders' Equity (Narrative) (Details) (USD $) Share data in Millions, unless otherwise specified	3 Months Ended
Mar. 31, 2012
Equity [Abstract]
Amount of Stock Retired Under the Current Stock Repurchase Program	$ 20,800,000
Number of Shares Retired Under the Current Stock Repurchase Program	0.4
Authorized Common Stock Repurchase Program	$ 5,000,000,000

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet68.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Product Sales) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Segment Reporting Information [Line Items]
Product Sales	$ 2,208,342	$ 1,863,578
Atripla [Member]
Segment Reporting Information [Line Items]
Product Sales	887,596	744,512
Truvada [Member]
Segment Reporting Information [Line Items]
Product Sales	758,263	673,111
Viread [Member]
Segment Reporting Information [Line Items]
Product Sales	191,693	168,395
Complera/Eviplera [Member]
Segment Reporting Information [Line Items]
Product Sales	52,180	0
Hepsera [Member]
Segment Reporting Information [Line Items]
Product Sales	29,297	38,096
Emtriva [Member]
Segment Reporting Information [Line Items]
Product Sales	6,777	6,576
Antiviral Products [Member]
Segment Reporting Information [Line Items]
Product Sales	1,925,806	1,630,690
AmBisome [Member]
Segment Reporting Information [Line Items]
Product Sales	84,764	78,506
Letairis [Member]
Segment Reporting Information [Line Items]
Product Sales	87,288	62,174
Ranexa [Member]
Segment Reporting Information [Line Items]
Product Sales	83,201	68,293
Other Products [Member]
Segment Reporting Information [Line Items]
Product Sales	$ 27,283	$ 23,915

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet69.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Schedule Of Revenues From Each Customer Who Individually Accounted For 10% Or More Of Total Revenues) (Details)	3 Months Ended
Mar. 31, 2012	Mar. 31, 2011
Cardinal Health, Inc. [Member]
Segment Reporting Information [Line Items]
Percentage of Total Revenues from Customers	20.00%	17.00%
McKesson Corp. [Member]
Segment Reporting Information [Line Items]
Percentage of Total Revenues from Customers	16.00%	15.00%
AmerisourceBergen Corp. [Member]
Segment Reporting Information [Line Items]
Percentage of Total Revenues from Customers	11.00%	13.00%

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet70.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Segment Information (Narrative) (Details)	3 Months Ended
Mar. 31, 2012
Segment Reporting [Abstract]
Major Customers Percentage of Total Revenues, Minimum	10.00%

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/Sheet71.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

Income Taxes (Details)	3 Months Ended
Mar. 31, 2012
Income Tax Disclosure [Abstract]
Income Tax Rate	34.60%
Federal Income Tax Rate	35.00%

------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287 Content-Location: file:///C:/9495dfdb_c740_4a21_9520_9ab9cbc00287/Worksheets/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" ------=_NextPart_9495dfdb_c740_4a21_9520_9ab9cbc00287--